Comerica Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.61M | Sell |
4,040
-7,750
| -66% | -$3.43M | 0.01% | 1231 |
|
|
2025
Q3 | $5.38M | Sell |
11,790
-6,827
| -37% | -$2.78M | 0.02% | 651 |
|
|
2025
Q2 | $6.07M | Buy |
18,617
+1,364
| +8% | +$377K | 0.02% | 600 |
|
|
2025
Q1 | $4.66M | Buy |
17,253
+3,262
| +23% | +$838K | 0.02% | 705 |
|
|
2024
Q4 | $3.29M | Buy |
13,991
+12,079
| +632% | +$3.18M | 0.01% | 900 |
|
|
2024
Q3 | $526K | Sell |
1,912
-10,676
| -85% | -$2.78M | ﹤0.01% | 1865 |
|
|
2024
Q2 | $3.06M | Sell |
12,588
-415
| -3% | -$65.5K | 0.01% | 936 |
|
|
2024
Q1 | $1.94M | Sell |
13,003
-360
| -3% | -$60.1K | 0.01% | 1190 |
|
|
2023
Q4 | $2.56M | Sell |
13,363
-63
| -0.5% | -$10.7K | 0.01% | 1032 |
|
|
2023
Q3 | $2.38M | Buy |
+13,426
| New | +$2.56M | 0.01% | 990 |
|
|
2022
Q4 | $2.75M | Buy |
11,761
+34
| +0.3% | +$7.25K | 0.02% | 901 |
|
|
2022
Q3 | $2.3M | Buy |
11,727
+61
| +0.5% | +$11.6K | 0.02% | 966 |
|
|
2022
Q2 | $1.7M | Hold |
11,666
| – | – | 0.01% | 1210 |
|
|
2022
Q1 | $1.96M | Sell |
11,666
-9
| -0.1% | -$1.37K | 0.01% | 1161 |
|
|
2021
Q4 | $1.53M | Sell |
11,675
-2
| -0% | -$372 | 0.01% | 1331 |
|
|
2021
Q3 | $2.32M | Sell |
11,677
-3,304
| -22% | -$620K | 0.01% | 1192 |
|
|
2021
Q2 | $2.95M | Sell |
14,981
-196
| -1% | -$28.7K | 0.02% | 1060 |
|
|
2021
Q1 | $2.08M | Sell |
15,177
-409
| -3% | -$61.5K | 0.01% | 1333 |
|
|
2020
Q4 | $2.69M | Sell |
15,586
-345
| -2% | -$46.1K | 0.02% | 1119 |
|
|
2020
Q3 | $2.1M | Sell |
15,931
-110
| -0.7% | -$15.6K | 0.02% | 1109 |
|
|
2020
Q2 | $2.53M | Sell |
16,041
-4,746
| -23% | -$640K | 0.02% | 922 |
|
|
2020
Q1 | $3.03M | Sell |
20,787
-3,733
| -15% | -$431K | 0.03% | 666 |
|
|
2019
Q4 | $2.83M | Sell |
24,520
-1,296
| -5% | -$129K | 0.02% | 887 |
|
|
2019
Q3 | $2.29M | Sell |
25,816
-5,643
| -18% | -$446K | 0.02% | 1007 |
|
|
2019
Q2 | $2.29M | Buy |
31,459
+4,156
| +15% | +$319K | 0.02% | 1009 |
|
|
2019
Q1 | $2.48M | Buy |
27,303
+1,636
| +6% | +$137K | 0.02% | 973 |
|
|
2018
Q4 | $2.03M | Buy |
25,667
+3,579
| +16% | +$275K | 0.02% | 1089 |
|
|
2018
Q3 | $1.69M | Buy |
22,088
+5,956
| +37% | +$599K | 0.01% | 1250 |
|
|
2018
Q2 | $1.65M | Buy |
16,132
+22
| +0.1% | +$2.18K | 0.01% | 1385 |
|
|
2018
Q1 | $1.55M | Sell |
16,110
-47
| -0.3% | -$6.06K | 0.01% | 1388 |
|
|
2017
Q4 | $2.16M | Buy |
16,157
+272
| +2% | +$34.2K | 0.01% | 1223 |
|
|
2017
Q3 | $1.95M | Buy |
15,885
+198
| +1% | +$16.9K | 0.01% | 1235 |
|
|
2017
Q2 | $1.31M | Sell |
15,687
-54
| -0.3% | -$3.45K | 0.01% | 1434 |
|
|
2017
Q1 | $831K | Sell |
15,741
-528
| -3% | -$24.4K | 0.01% | 1682 |
|
|
2016
Q4 | $677K | Buy |
16,269
+2,712
| +20% | +$114K | 0.01% | 1742 |
|
|
2016
Q3 | $491K | Sell |
13,557
-157
| -1% | -$11.1K | ﹤0.01% | 1787 |
|
|
2016
Q2 | $1.05M | Buy |
13,714
+31
| +0.2% | +$1.95K | 0.01% | 1470 |
|
|
2016
Q1 | $941K | Buy |
13,683
+89
| +0.7% | +$5.92K | 0.01% | 1507 |
|
|
2015
Q4 | $1.15M | Sell |
13,594
-233
| -2% | -$21.6K | 0.01% | 1323 |
|
|
2015
Q3 | $1.11M | Sell |
13,827
-13,697
| -50% | -$1.52M | 0.01% | 1382 |
|
|
2015
Q2 | $3.3M | Buy |
27,524
+13,814
| +101% | +$1.65M | 0.01% | 1220 |
|
|
2015
Q1 | $1.43M | Sell |
13,710
-13,656
| -50% | -$1.38M | 0.01% | 1287 |
|
|
2014
Q4 | $2.65M | Buy |
27,366
+13,683
| +100% | +$1.27M | 0.01% | 1315 |
|
|
2014
Q3 | $1.07M | Sell |
13,683
-37
| -0.3% | -$2.39K | 0.01% | 1454 |
|
|
2014
Q2 | $867K | Sell |
13,720
-4,540
| -25% | -$270K | 0.01% | 1576 |
|
|
2014
Q1 | $1.23M | Buy |
18,260
+13
| +0.1% | +$1.01K | 0.01% | 1424 |
|
|
2013
Q4 | $1.17M | Sell |
18,247
-1,544
| -8% | -$92.1K | 0.01% | 1456 |
|
|
2013
Q3 | $1.27M | Sell |
19,791
-86
| -0.4% | -$4.29K | 0.01% | 1473 |
|
|
2013
Q2 | $616K | Buy |
+19,877
| New | +$529K | 0.01% | 1642 |
|
Other funds holding ALNY
Comerica Bank's ALNY Position: Q4 2025 in Review
Comerica Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 66% in Q4 2025, selling an estimated $3.43M and leaving 4,040 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #1231.
Comerica Bank first reported a position in ALNY in Q2 2013 and has held it in 49 quarters since. The position peaked at $6.07M in Q2 2025. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.
- Comerica Bank held 4,040 shares of Alnylam Pharmaceuticals worth $1.61M as of Q4 2025.
- Comerica Bank sold 7,750 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $3.43M.
- Alnylam Pharmaceuticals made up 0.01% of Comerica Bank's portfolio in Q4 2025, its #1231 holding.
- Comerica Bank first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Comerica Bank's Alnylam Pharmaceuticals position peaked at $6.07M in Q2 2025.
- 849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.
Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.